Christof Fellman, investigator portrait

CRISPR-Cas engineering to unravel cellular signaling in cancer progression and therapy

The Fellmann Lab focuses on unraveling organizational principles of cellular signaling networks in cancer progression and therapy. Fellmann’s work has centered on better understanding RNA-guided immune systems, including RNAi and CRISPR-Cas machinery, and leveraging them to dissect cancer, with a particular focus on RAS-mutant tumors and glioblastoma. His lab studies the mechanistic interplay between CRISPR‐Cas enzymes and mammalian DNA repair pathways to pioneer innovative approaches for genome manipulation and precision medicine. Fellmann and his team apply these methods to study the plasticity of cellular signaling networks and their rewiring in cancers, with the ultimate goal of translating insights into clinically actionable strategies to treat patients.


More Publications